Silverarc Capital Management’s Structure Therapeutics GPCR Stock Holding History

Silverarc Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-175,636	Closed	-$3.64M	–	86
2025 Q2	$3.64M	Sell	175,636 -12,433	-7%	-$273K	0.67%	35
2025 Q1	$3.26M	Buy	188,069 +35,674	+23%	+$874K	0.67%	42
2024 Q4	$4.13M	Buy	152,395 +81,879	+116%	+$2.91M	0.9%	35
2024 Q3	$3.09M	Hold	70,516	–	–	0.7%	41
2024 Q2	$2.77M	Buy	70,516 +60,516	+605%	+$2.48M	0.65%	38
2024 Q1	$429K	Buy	+10,000	New	+$422K	0.12%	70

Other funds holding GPCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Silverarc Capital Management's GPCR Position: Q3 2025 in Review

Silverarc Capital Management sold out of Structure Therapeutics (GPCR) in Q3 2025, closing a stake of 175,636 shares — an estimated $3.64M sold.

Silverarc Capital Management first reported a position in GPCR in Q1 2024 and held it in 6 quarters. The position peaked at $4.13M in Q4 2024. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

Silverarc Capital Management reported no remaining Structure Therapeutics position as of Q3 2025 after selling out during the quarter.
Silverarc Capital Management sold 175,636 Structure Therapeutics shares in Q3 2025, an estimated $3.64M.
Silverarc Capital Management first reported a position in Structure Therapeutics in Q1 2024 and held it in 6 quarters.
Silverarc Capital Management's Structure Therapeutics position peaked at $4.13M in Q4 2024.
156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on Silverarc Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.